ContextVision is a medical technology company specializing in image analysis and artificial intelligence. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment.
As an industry pioneer for more than 30 years, ContextVision is taking a leading position within deep learning, the latest artificial intelligence technology, to broaden its product portfolio and enter a new rapidly growing market – digital pathology.
ContextVision intends to become a game changer within digital pathology by developing a set of decision support tools. The first product, for prostate cancer, is expected to be ready for the market by the end of 2018.
ContextVision is based in Sweden, with local presentation in the U.S., Russia, Japan, China and Korea.
ContextVision is listed on the Oslo Stock Exchange under the ticker COV.